A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-02-10
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in
adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL).
The study will be conducted in 2 parts: Part A, monotherapy dose escalation and Part B,
monotherapy dose expansion.
Parts A and B will consist of 3 periods: Screening, Treatment, and Follow-up.